Why is Moderna stock sliding today?

Moderna's stock is experiencing a significant decline of nearly 5.9% in early trading today following Citi's downgrade to Sell with a lowered price target of $80. Analyst Geoff Meacham increased the target from $60, indicating a potential 60% downside from Tuesday's close. The downgrade is particularly notable as Moderna had only two sell ratings among many analysts, making Citi's shift a significant change in institutional consensus.

The company's valuation comes under further scrutiny due to an unresolved patent infringement lawsuit filed by Bayer’s Monsanto division, alleging unauthorized use of Moderna's mRNA-related intellectual property. Additionally, a Delaware federal court denied Moderna's motion to dismiss the lawsuit on September 28, adding legal risk to the stock.

Despite the recent positive results from Moderna's personalized cancer vaccine trial and a 223% rally since August 19, broader market conditions provide little support for the stock, as the Nasdaq remains flat and the S&P 500 shows minimal gains. Peer sentiment in the mRNA sector is mixed, with companies like CanSino Biologics surging on anticipation of Moderna's upcoming ESMO data presentation, but not translating into buying interest for Moderna itself.

Combined, Citi's sell rating, unresolved patent litigation, and the lack of a clear near-term commercial or regulatory catalyst have led to a sharp drop in Moderna's shares in pre-market trading, leaving investors to question whether the stock's impressive growth can be sustained.